Literature DB >> 16963079

Structure of Leishmania mexicana phosphomannomutase highlights similarities with human isoforms.

Lukasz Kedzierski1, Robyn L Malby, Brian J Smith, Matthew A Perugini, Anthony N Hodder, Thomas Ilg, Peter M Colman, Emanuela Handman.   

Abstract

Phosphomannomutase (PMM) catalyses the conversion of mannose-6-phosphate to mannose-1-phosphate, an essential step in mannose activation and the biosynthesis of glycoconjugates in all eukaryotes. Deletion of PMM from Leishmania mexicana results in loss of virulence, suggesting that PMM is a promising drug target for the development of anti-leishmanial inhibitors. We report the crystallization and structure determination to 2.1 A of L. mexicana PMM alone and in complex with glucose-1,6-bisphosphate to 2.9 A. PMM is a member of the haloacid dehalogenase (HAD) family, but has a novel dimeric structure and a distinct cap domain of unique topology. Although the structure is novel within the HAD family, the leishmanial enzyme shows a high degree of similarity with its human isoforms. We have generated L. major PMM knockouts, which are avirulent. We expressed the human pmm2 gene in the Leishmania PMM knockout, but despite the similarity between Leishmania and human PMM, expression of the human gene did not restore virulence. Similarities in the structure of the parasite enzyme and its human isoforms suggest that the development of parasite-selective inhibitors will not be an easy task.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16963079     DOI: 10.1016/j.jmb.2006.08.023

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  10 in total

Review 1.  Structures of proteins of biomedical interest from the Center for Eukaryotic Structural Genomics.

Authors:  George N Phillips; Brian G Fox; John L Markley; Brian F Volkman; Euiyoung Bae; Eduard Bitto; Craig A Bingman; Ronnie O Frederick; Jason G McCoy; Betsy L Lytle; Brad S Pierce; Jikui Song; Simon N Twigger
Journal:  J Struct Funct Genomics       Date:  2007-09-06

Review 2.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

3.  Inhibitors of Leishmania GDP-mannose pyrophosphorylase identified by high-throughput screening of small-molecule chemical library.

Authors:  Kurt Lackovic; John P Parisot; Nerida Sleebs; Jonathan B Baell; Laurent Debien; Keith G Watson; Joan M Curtis; Emanuela Handman; Ian P Street; Lukasz Kedzierski
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

4.  Sugar nucleotide pools of Trypanosoma brucei, Trypanosoma cruzi, and Leishmania major.

Authors:  Daniel C Turnock; Michael A J Ferguson
Journal:  Eukaryot Cell       Date:  2007-06-08

5.  Production and crystallization of α-phosphoglucomutase from Lactococcus lactis.

Authors:  Przemyslaw Nogly; Rute Castro; Matteo de Rosa; Ana Rute Neves; Helena Santos; Margarida Archer
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-08-31

6.  Label-Free Quantitative Proteomic Analysis of Three Strains of Viscerotropic Leishmania Isolated from Patients with Different Epidemiological Types of Visceral Leishmaniasis in China.

Authors:  Fu-Rong Wei; Chun-Hua Gao; Jun-Yun Wang; Yue-Tao Yang; Feng Shi; Bin Zheng
Journal:  Acta Parasitol       Date:  2021-05-21       Impact factor: 1.440

7.  Phosphoglucomutase is absent in Trypanosoma brucei and redundantly substituted by phosphomannomutase and phospho-N-acetylglucosamine mutase.

Authors:  Giulia Bandini; Karina Mariño; M Lucia Sampaio Güther; Amy K Wernimont; Sabine Kuettel; Wei Qiu; Shamshad Afzal; Anna Kelner; Raymond Hui; Michael A J Ferguson
Journal:  Mol Microbiol       Date:  2012-07-12       Impact factor: 3.501

8.  Conformational response to ligand binding in phosphomannomutase2: insights into inborn glycosylation disorder.

Authors:  Giuseppina Andreotti; Israel Cabeza de Vaca; Angelita Poziello; Maria Chiara Monti; Victor Guallar; Maria Vittoria Cubellis
Journal:  J Biol Chem       Date:  2014-10-16       Impact factor: 5.157

Review 9.  The Potential of Secondary Metabolites from Plants as Drugs or Leads against Protozoan Neglected Diseases-Part III: In-Silico Molecular Docking Investigations.

Authors:  Ifedayo Victor Ogungbe; William N Setzer
Journal:  Molecules       Date:  2016-10-19       Impact factor: 4.411

10.  Trypanosoma cruzi Phosphomannomutase and Guanosine Diphosphate-Mannose Pyrophosphorylase Ligandability Assessment.

Authors:  Filip Zmuda; Sharon M Shepherd; Michael A J Ferguson; David W Gray; Leah S Torrie; Manu De Rycker
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.